Page 4 - அலுவலகம் ஆஃப் புற்றுநோயியல் நோய்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA Panel: Yank Keytruda Approval in Third-Line Gastric Cancer

email article An advisory committee recommended that the FDA revoke the accelerated approval for pembrolizumab (Keytruda) as a third-line option in gastric or gastroesophageal junction (GEJ) cancer. With a vote of 6-2, the Oncologic Drugs Advisory Committee (ODAC) on Thursday recommended against maintaining the PD-1 immune checkpoint inhibitor s indication for patients with metastatic or recurrent locally advanced gastric or GEJ cancers with tumors expressing PD-L1. Committee members overwhelmingly cited the new availability of a PD-1 inhibitor, in combination with chemotherapy, in the upfront setting, as well as the fact that patients who have already received chemotherapy alone as their initial therapy could still access pembrolizumab through expanded use programs.

United statesNew yorkMemorial sloan kettering cancer centerNew havenYale universityPamela kunzRichard pazdurColin weekesDiane reidy lagunesOncologic drugs advisory committeeUniversity of coloradoYale university school of medicineOffice of oncologic diseasesMassachusetts general hospitalChristopher lieuNew york city

FDA Watch: J&J Vaccinations Resume, Fake COVID-19 Therapies, Uterine Cancer Drug Fast-Tracked, Brie Cheese Recalls Over Salmonella Concern

Fact-Checked The FDA made several moves in April, from lifting the pause on the J&J vaccine to recalls on certain pills and vitamins. Bakhtiar Zein/iStock COVID-Related News The CDC and FDA have lifted the pause of the Johnson & Johnson vaccine following a complete review of rare blood clots. Following a thorough safety review including two meetings of the Centers for Disease Control and Prevention s (CDC) Advisory Committee on Immunization Practices the U.S. Food and Drug Administration (FDA) and the CDC issued a statement on April 23 saying that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the United States should be lifted. Most States have resumed use of the vaccine.

Richard pazdurCarefusion alarisChristopherm loftusDostarlimab jemperliOncology centerRadiological healthOffice of neurologicalOffice of oncologic diseasesOncologic diseasesDrug evaluationIpsihand systemPhysical medicine devicesபுற்றுநோயியல் மையம்கதிரியக்கவியல் ஆரோக்கியம்அலுவலகம் ஆஃப் நரம்பியல்அலுவலகம் ஆஃப் புற்றுநோயியல் நோய்கள்

FDA approves Jemperli for advanced endometrial cancer

FDA approves Jemperli for advanced endometrial cancer
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Richard pazdurGlaxosmithkline jemperliOncology centerDrug administrationOffice of oncologic diseasesOncologic diseasesDrug evaluationபுற்றுநோயியல் மையம்அலுவலகம் ஆஃப் புற்றுநோயியல் நோய்கள்புற்றுநோயியல் நோய்கள்மருந்து மதிப்பீடு

FDA Approves Immunotherapy for Endometrial Cancer with Specific Biomarker

FDA Approves Immunotherapy for Endometrial Cancer with Specific Biomarker
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesRichard pazdurChanapa tantibanchachaiOncology centerDrug administrationOffice of oncologic diseasesOncologic diseasesDrug evaluationPriority reviewBreakthrough therapyAccelerated approvalஒன்றுபட்டது மாநிலங்களில்புற்றுநோயியல் மையம்அலுவலகம் ஆஃப் புற்றுநோயியல் நோய்கள்புற்றுநோயியல் நோய்கள்மருந்து மதிப்பீடு

FDA approves immunotherapy for treating patients with dMMR endometrial cancer

FDA approves immunotherapy for treating patients with dMMR endometrial cancer Today, the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR (which contain abnormalities that affect the proper repair of DNA inside the cell), as determined by an FDA-approved test. Today s approval of Jemperli is evidence of the FDA s progress in applying precision medicine to expand treatment options for patients with cancer. This immunotherapy was specifically studied to target dMMR endometrial cancer and leverages scientific knowledge surrounding the mechanism of immunotherapy response in this unmet medical need population.

United statesRichard pazdurEmily hendersonOncology centerDrug administrationOffice of oncologic diseasesActing directorOncologic diseasesDrug evaluationPriority reviewBreakthrough therapyAccelerated approvalஒன்றுபட்டது மாநிலங்களில்எமிலி ஹென்டர்சன்புற்றுநோயியல் மையம்அலுவலகம் ஆஃப் புற்றுநோயியல் நோய்கள்